Ahead Of The Bell: Indaptus Therapeutics (Nasdaq: INDP) is Topping Our Watchlist Right Now—Here’s Why

*Sponsored Just Announced! Indaptus Therapeutics (Nasdaq: INDP) Is Our Next Potential Breakout Idea  For This Morning—Tuesday, 3/25/2025. Here’s What We Can Tell You—So Far… Low Float & Market Cap: With A Market Cap Hovering Around $10M And A Float Of Approximately 12M Shares, Volatility Could Be A Factor If More Attention Builds. Analyst Coverage: In Their Latest Report Published On Friday, 3/21/2025, Maxim Group Listed A $5 Target For (INDP), Which Suggests 594% Upside Potential From Its Recent $.72 Range. Advancing Immunotherapy Innovation: The Decoy Platform Is Designed To Stimulate Both Innate And Adaptive Immune Responses, Advancing A Next-Generation Approach In Immunotherapy. Key Clinical Trial Milestone: A Phase 1b/2 Combination Trial Is Now Underway, Testing Decoy20 With BeiGene’s PD-1 Checkpoint Inhibitor, Tislelizumab In Advanced Solid Tumors.  Multiple Upcoming Catalysts Are Expected In 2025. Consider Adding Indaptus Therapeutics (Nasdaq: INDP) To Your Radar This Morning And Start Your Own Research While It’s Still Early. March 25, 2025 Dear Reader, Here we are—ahead of the bell. And in case you didn’t know yet— Indaptus Therapeutics (Nasdaq: INDP) is topping our watchlist right now. There’s something different about this one. It’s got that familiar low-float structure, the tight range, and just enough coverage to stay off most radar screens—but not for much longer.  In fact, one well-known biotech analyst has set a $5 target on this company—which suggests a potential upside of over 594% from its recent $.72 range. With that, we’re ready to reveal what’s next. Introducing our latest potential breakout idea: Indaptus Therapeutics (Nasdaq: INDP). With a market cap hovering around $10M and a float of approximately 12M shares, this one has the kind of structure that’s historically had the potential for explosive moves. Keep reading to see why Indaptus Therapeutics (Nasdaq: INDP) is topping our watchlist this morning—Tuesday, 3/25/2025. This isn’t just about numbers—it’s about what’s happening behind the scenes.  Indaptus Therapeutics (Nasdaq: INDP) is advancing a next-generation immunotherapy approach, has recently secured key patents, and just launched a major Phase 1b/2 trial alongside a well-established industry player. Let’s take a closer look at what’s unfolding… Indaptus Therapeutics (Nasdaq: INDP) is advancing a next-generation approach to immunotherapy, building on over a century of research into harnessing the immune system to combat cancer and chronic viral infections. The company’s Decoy platform has demonstrated the ability to activate multiple immune system pathways with intravenous (i.v.) administration, representing a potential breakthrough in cancer and infectious disease treatment.  At its core, Indaptus Therapeutics, Inc. (Nasdaq: INDP)’s technology is designed to simultaneously stimulate innate and adaptive immune responses, a key factor in overcoming complex diseases. Rethinking Immunotherapy: How Indaptus Therapeutics (Nasdaq: INDP) is Activating the Immune System Differently… Unlike many traditional immunotherapies that focus on a single pathway or immune target, Indaptus is doing something different.  Their approach delivers a multi-targeted immune activation system—engineered to stimulate the immune system broadly, while also designed to keep toxicity in check.  It’s a carefully balanced strategy that aims to activate the right immune responses without overwhelming the patient. At the heart of this innovation is their patented Decoy platform.  Indaptus Therapeutics (Nasdaq: INDP) has developed it using attenuated, non-pathogenic bacteria that are able to safely engage several key immune receptors simultaneously.  What makes it exciting is that this technology isn’t limited to one type of immune pathway—it taps into Toll-like receptors (TLR), NOD-like receptors (NLR), and the STING pathway to drive a stronger, more coordinated immune response. The Decoy platform is designed for intravenous use, which is notable given how bacterial-based therapies have traditionally struggled with toxicity issues when delivered this way.  So far, Decoy has shown strong immune activation in pre-clinical models, but with reduced toxicity—something that’s difficult to achieve in this space. It’s also shown versatility.  In pre-clinical studies, the platform produced activity across a range of cancers—including breast, colorectal, pancreatic, and liver tumors—as well as in chronic viral infections like Hepatitis B and HIV.   One particularly promising feature is its ability to convert “cold” tumors (which don’t respond well to treatment) into “hot” tumors that are inflamed and more likely to respond to immunotherapy. That could make it a great candidate for combination use with other treatments like PD-1 checkpoint inhibitors or chemotherapy—and that’s exactly what they’re testing now. Decoy20, their lead clinical candidate, is currently being evaluated in a Phase 1 trial for advanced solid tumors. More than 20 patients have already been enrolled in the weekly dosing cohort.  So far, early signs of benefit have been observed, including some patients achieving Stable Disease—an encouraging sign in early-stage cancer trials.  The pharmacokinetics and biomarker data have also come in stronger than expected, and the safety profile remains favorable. Now, the company has taken the next step—officially launching a combination trial that pairs Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab.   It’s a big moment for Indaptus Therapeutics (Nasdaq: INDP), as this new phase could help unlock the full potential of their platform in real-world patient settings. The Wait Is Over: Indaptus Enters Real-World Testing With Decoy20 and Tislelizumab… A major new chapter is underway for Indaptus Therapeutics (Nasdaq: INDP).  The company has officially launched a Phase 1b/2 combination trial that pairs its lead candidate, Decoy20, with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab.  This marks a critical shift—from pre-clinical success in the lab to real-world patient testing. It’s a meaningful step. Until now, Decoy20 has shown strong potential on its own in pre-clinical studies.  But now the focus is on testing how it performs in combination with a widely used immunotherapy agent.  The goal?  To see whether Decoy20 can enhance the immune system’s response and potentially make checkpoint inhibitors more effective and longer-lasting—especially for patients who don’t respond well to those treatments alone. The trial is designed to start with a week of Decoy20 administered on its own. From there, patients will begin combination therapy with tislelizumab.  The first few participants will be enrolled gradually to monitor safety, and once approved by the trial’s safety committee, broader enrollment will begin.  Patients will remain on treatment for up to a year—or until the disease progresses, side effects become unacceptable, or they decide to withdraw. This is a pivotal moment for Indaptus Therapeutics (Nasdaq: INDP).  The move into a combination study signals the company’s confidence in Decoy20’s platform—and its potential to play a central role in the future of immunotherapy.  For now, all attention turns to the data ahead. Fresh Patents Help Indaptus Therapeutics (Nasdaq: INDP) Protect Its Breakthrough Decoy Platform… In the biotech world, protecting innovation is everything—and Indaptus Therapeutics (Nasdaq: INDP) is clearly making moves to secure its place.  The company has recently expanded its intellectual property footprint with new patents granted in China, Japan, and Israel.  These patents cover its Decoy bacterial compositions specifically aimed at targeting Hepatitis B (HBV) and HIV, two areas where immune-based treatments are still very much needed. This kind of patent expansion does more than just protect the science.  It reinforces Indaptus Therapeutics (Nasdaq: INDP)’s position as a leader in the space and creates room to explore future commercialization in some of the world’s most important healthcare markets.  With this growing portfolio, the company is laying the groundwork for long-term value—and possibly some compelling licensing potential down the line. Fiscal Positioning & What’s Ahead… Indaptus Therapeutics (Nasdaq: INDP) has been keeping a tight grip on its fiscal operations—showing discipline in how it funds operations while still moving its clinical programs forward.  As of December 31, 2024, the company reported $5.8M in ca-sh and ca-sh equivalents. Over the past year, it completed multiple funding rounds, including registered direct offerings and an equity line, which helped boost flexibility without compromising long-term goals. In early 2025, Indaptus Therapeutics (Nasdaq: INDP) also secured a $20M equity line with Yorkville, giving it additional breathing room to continue executing on its pipeline.  With this setup, the company is in a solid position to carry its current plans into the second quarter of the year and potentially beyond. Looking ahead, 2025 could shape up to be a big one. Now that the Decoy20 combination study with tislelizumab is underway, the next steps include enrolling more patients and expanding the number of trial sites to speed things up.  Indaptus Therapeutics (Nasdaq: INDP) is also expecting additional clinical updates as the Phase 1 trial progresses—particularly around safety and efficacy data. And if all goes as planned, the company may be ready to announce a new Decoy platform candidate for IND-enabling studies later this year. With multiple near-term inflection points, Indaptus Therapeutics (Nasdaq: INDP) is entering a pivotal phase of growth, setting the stage for its long-term impact in oncology and infectious disease immunotherapy. 7 Reasons Why Indaptus Therapeutics (Nasdaq: INDP) is Topping  Our This Morning, 3/25/2025… 1. Low Float & Market Cap: With a market cap hovering around $10M and a float of approximately 12M shares, Indaptus Therapeutics (Nasdaq: INDP) has the type of structure where volatility could become a key factor if more attention builds. 2. Analyst Coverage: In a report published on March 21, 2025, Indaptus Therapeutics (Nasdaq: INDP) was listed as having a $5 target by Maxim Group analyst Jason McCarthy, Ph.D., which suggests over 594% upside potential from its recent $.72 range. 3. Key Clinical Trial Milestone: A Phase 1b/2 combination trial has now officially begun, testing Decoy20 alongside BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, marking a critical step forward in the clinical pipeline for Indaptus Therapeutics, Inc. (Nasdaq: INDP). 4. Expanding Intellectual Property: New patents covering Decoy bacteria compositions for Hepatitis B (HBV) and HIV have been granted in China, Japan, and Israel, further strengthening the position of Indaptus Therapeutics (Nasdaq: INDP) in bacterial-based immunotherapy. 5. Advancing Immunotherapy Innovation: A next-generation immunotherapy approach is taking shape with the Decoy platform, a technology designed to stimulate both innate and adaptive immune responses—a fundamental advancement being pursued by Indaptus Therapeutics, Inc. (Nasdaq: INDP). 6.⁠ ⁠Backed By Fresh Capital: As of December 31, 2024, reported cash holdings stood at $5.8M, while a newly established $20M equity line with Yorkville provides extended flexibility for Indaptus Therapeutics (Nasdaq: INDP) into Q2 2025. 7. Multiple Upcoming Catalysts: A series of anticipated milestones in 2025—including new clinical data releases, trial site expansions, and the potential nomination of another Decoy platform candidate—are all developments to watch for Indaptus Therapeutics, Inc. (Nasdaq: INDP). Put Indaptus Therapeutics (Nasdaq: INDP) on Your Radar This Morning  and Start Your Own Research While It’s Still Early… Some situations don’t stay quiet for long—and Indaptus Therapeutics (Nasdaq: INDP) is starting to check too many boxes to ignore. With a $5 target from a well-followed biotech analyst, a float of approx. 12M shares, and a market cap still hovering around $10M, this is the kind of structure that tends to get interesting fast when momentum builds. Now factor in a Phase 1b/2 trial underway with a major checkpoint inhibitor, a fresh batch of international patents, and positioning that could set the tone for a very active 2025—and it’s not hard to see why this one just hit our radar. We have all eyes on (INDP) this morning. You may want to take a look at (INDP) before the bell rings. Also—keep an eye out for my next update—it could be on its way to you very shortly. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: stocknewstrends.com/disclosure/  *Pursuant to an agreement between TD Media LLC and LFG Equities Corp., TD Media LLC has been hired for a period beginning on 03/25/2025 and ending on 03/25/2025 to publicly disseminate information about (INDP:US) via digital communications. Under this agreement, TD Media LLC has been paid twenty two thousand five hundred USD (“Funds”). To date, including under the previously described agreement, TD Media LLC has been paid forty five thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither TD Media LLC and their member own shares of (INDP:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/indp/#details

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice